Trial · NCT05497102
Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT
NCT05497102, Phase 2, Unknown, Samsung Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT. Trials, record NCT05497102. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05497102
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT
- NCT number
- NCT05497102
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 58 participants, estimated
- Lead sponsor
- Samsung Medical Center
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide maintenance
- First posted
- 2022-08-11
- Last updated
- 2022-08-12
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 2-year progression free survival rate | 2-years after the written consent | percentage of patients who are disease free or alive at 2-years |
| Secondary | Complete response rate after KRd #6 | total 6 cycles (each cycle is 28 days) of induction therapy | percentage of patients who achieve complete response |
| Secondary | Complete response rate after ASCT | at the time of 2nd ASCT (within 60 days after ASCT) | percentage of patients who achieve complete response |
| Secondary | Overall response rate | assessed for approximately 3 years after administration | percentage of patients who achieve at least partial response |
| Secondary | Time to response | assessed for approximately 3 years after administration | from the time of written consent to the time of achieving at least partial response |
| Secondary | Duration of response | assessed for approximately 3 years after administration | from the time of achieving at least partial response to the time of progressive disease |
| Secondary | Overall survival | assessed for approximately 3 years after administration | from the time of written consent to the time of death or last follow-up |
| Secondary | Safety of KRd induction therapy, 2nd ASCT, and lenalidomide maintenance therapy | assessed for approximately 2 years during administration | treatment-emergent adverse events |
| Secondary | Rate of the successful stem cell harvest | total 6 cycles (each cycle is 28 days) of induction therapy | percentage of patients who collected cluster of differentiation(CD34+) hematopoietic stem cells \> 2 x 10\^6 cells/kg |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05497102
GET https://conductscience.org/api/trials/v1/NCT05497102/registered